查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1573116

癌症生技藥品市場：依治療藥物、細胞治療藥物、癌症疫苗分類 - 全球預測 2025-2030

Cancer Biologics Market by Therapies, Cell Therapies, Cancer Vaccines - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癌症生技藥品市場規模為967.1億美元，預計2024年將達到1,020.5億美元，複合年成長率為6.30%，2030年將達到1,483.5億美元。

癌症生技藥品是製藥業中快速發展的一個領域，專注於使用比傳統化療更精確地針對癌細胞的生物物質和系統。這些生物製藥包括單株抗體、生長因子抑制劑、基因療法和個人化疫苗。這種需求源於對標靶治療的需求，以最大限度地減少對健康細胞的附帶損害、改善患者的治療效果並減少副作用。癌症生技藥品的應用範圍從治療到診斷再到預後，最終用途包括醫院、診所和專門的癌症治療中心。

主要市場統計
基準年[2023] 967.1億美元
預測年份 [2024] 1020.5億美元
預測年份 [2030] 1483.5億美元
複合年成長率（%） 6.30%

癌症生技藥品市場是由癌症發生率上升、生物技術進步以及研發投資快速增加所推動的。關鍵的成長要素包括擴大新興國家的醫療保健覆蓋範圍、對生物製藥的監管支持以及意識提升。一個潛在的機會在於開發具有成本效益的生物相似藥來取代品牌生技藥品。為了抓住這個機會，公司必須投資強力的臨床試驗並有效地通過生物相似藥核准途徑。此外，利用人工智慧和機器學習進行生物標記發現可以促進個人化醫療的方法，提供顯著的成長前景。

然而，該市場面臨一些挑戰，包括高昂的開發成本、嚴格的監管要求以及製造生物製藥的複雜性。智慧財產權和市場競爭也是主要障礙，這可能導致限制可及性的高定價策略。為了實現永續成長，創新者應專注於提高製造效率和擴大合作研究夥伴關係。

有前景的創新領域包括利用 CRISPR 技術進行基因編輯探索新的治療標靶，以及研究微生物組在癌症治療中的作用。了解競爭格局和市場的本質（其特點是快速發展和激烈競爭）使公司能夠制定有效的策略並進行創新。透過應對挑戰和利用新技術進步，公司可以利用癌症生技藥品帶來的快速成長機會。

市場動態：揭示快速發展的癌症生技藥品市場的關鍵市場洞察

供需的動態交互作用正在改變癌症生技藥品市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 加強關注早期癌症檢測和個人化治療
    • 生物製藥製造的技術進步提高了成本效率和生產力
    • 學術機構與生物製藥公司加強癌症藥物創新合作
    • 新興市場醫療保健基礎設施的擴大和生技藥品的獲取增加有助於市場成長
  • 市場限制因素
    • 複雜的供應鏈和冷藏保管物流帶來了配送挑戰並增加了成本
    • 報銷和承保範圍限制限制了患者獲得昂貴的生技藥品治療
  • 市場機會
    • 免疫療法技術的進步提高了治療效果和市場滲透率
    • 透過整合人工智慧和機器學習對癌症生技藥品進行預測分析
    • 由於診斷能力的提高，癌症生技藥品在新興市場的擴張
  • 市場挑戰
    • 由於生技藥品複雜的監管核准流程導致市場准入延遲
    • 獲得可靠的臨床試驗資料來證明生技藥品的有效性和安全性是一項挑戰

波特五力：駕馭癌症生技藥品市場的策略工具

波特的五力架構是了解癌症生技藥品市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解癌症生技藥品市場的外部影響

外部宏觀環境因素在塑造生技藥品市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解生技藥品市場的競爭格局

癌症生技藥品市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣生技藥品市場供應商的績效評估

FPNV定位矩陣是評估生技藥品市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃生技藥品市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，癌症生技藥品市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 加強關注早期癌症檢測和個人化治療方案
      • 生物製藥製造的技術進步提高了成本效率和生產力。
      • 加強學術機構與生物製藥公司合作創新癌症治療藥物
      • 擴大新興市場的醫療基礎設施和生技藥品的取得有助於市場成長
    • 抑制因素
      • 複雜的供應鏈和冷藏物流帶來了配送挑戰並增加了成本
      • 報銷和保險範圍的限制使患者無法接受昂貴的生物製藥治療。
    • 機會
      • 免疫療法技術的進步提高了治療效果和市場滲透率
      • 將人工智慧和機器學習整合到生技藥品中進行預測分析
      • 由於診斷能力的提高，癌症生技藥品在新興市場的擴張
    • 任務
      • 癌症生技藥品複雜的監管核准流程延遲了市場進入
      • 獲得可靠的臨床試驗資料以證明生技藥品的有效性和安全性面臨的挑戰
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章癌症生技藥品市場治療

  • 雙特異性單株抗體
  • 結合單株抗體
    • 化學標記抗體
    • 放射性標記抗體
  • 單株抗體

第7章癌症生技藥品市場細胞療法

  • 樹突細胞療法
  • 自然殺手細胞療法
  • T細胞療法

第8章癌症生技藥品市場癌症疫苗

  • 癌症預防疫苗
  • 治療性癌症疫苗

第9章美洲生技藥品市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太癌症生技藥品市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的癌症生技藥品市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C014D

The Cancer Biologics Market was valued at USD 96.71 billion in 2023, expected to reach USD 102.05 billion in 2024, and is projected to grow at a CAGR of 6.30%, to USD 148.35 billion by 2030.

Cancer biologics represent a rapidly evolving segment within the pharmaceutical industry, focused on using biological substances or systems to target cancer cells more precisely than traditional chemotherapies. These biologics include monoclonal antibodies, growth factor inhibitors, gene therapy, and personalized vaccines. Their necessity stems from the need for targeted therapeutics that minimize collateral damage to healthy cells, enhancing patient outcomes and reducing adverse effects. The application of cancer biologics spans from treatment to diagnostics and prognostics, with end-use scope including hospitals, clinics, and specialized cancer treatment centers.

KEY MARKET STATISTICS
Base Year [2023] USD 96.71 billion
Estimated Year [2024] USD 102.05 billion
Forecast Year [2030] USD 148.35 billion
CAGR (%) 6.30%

The market for cancer biologics is being driven by increasing cancer prevalence, advancements in biotechnology, and a surge in R&D investments. Key growth factors include expanded healthcare access in emerging economies, regulatory support for biological drugs, and increasing patient awareness. One potential opportunity lies in the development of biosimilars, offering cost-effective alternatives to branded biologics. To seize this opportunity, companies should invest in robust clinical trials and navigate the biosimilar approval pathways effectively. Additionally, leveraging AI and machine learning for biomarker discovery can expedite personalized medicine approaches, offering significant growth prospects.

However, several challenges confront the market, including high development costs, stringent regulatory requirements, and the complexity of manufacturing biological products. Intellectual property and market competition also pose substantial hurdles, potentially leading to high pricing strategies that limit accessibility. For sustained growth, innovators should focus on improving manufacturing efficiencies and expanding collaborative research partnerships.

Promising areas of innovation include the exploration of novel therapeutic targets using CRISPR technology for gene editing and investigating the microbiome's role in cancer therapy. Understanding the competitive landscape and the nature of the market, which is characterized by rapid advancements and high competition, can position companies to effectively strategize and innovate. By addressing the challenges and leveraging emerging technological advancements, businesses can capitalize on the burgeoning opportunities presented by cancer biologics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Biologics Market

The Cancer Biologics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising number of initiatives focused on early cancer detection and personalized treatment options
    • Technological advancements in biologic drug manufacturing leading to cost efficiency and higher production rates
    • Increasing collaborations between academic institutions and biopharmaceutical companies for cancer drug innovation
    • Expansion of healthcare infrastructure and access to biologics in emerging markets contributing to market growth
  • Market Restraints
    • Complex supply chain and cold storage logistics create challenges in distribution and increase costs
    • Reimbursement and insurance coverage restrictions limit patient access to expensive biologics treatments
  • Market Opportunities
    • Advancement in immunotherapy techniques enhancing treatment effectiveness and market penetration
    • Integrating artificial intelligence and machine learning in cancer biologics for predictive analytics
    • Expansion of cancer biologics in emerging markets due to increased diagnostic capabilities
  • Market Challenges
    • Navigating complex regulatory approval processes for cancer biologics causing delays in market entry
    • Challenges in obtaining robust clinical trial data for proving the efficacy and safety of cancer biologics

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Biologics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Biologics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Biologics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Biologics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Biologics Market

A detailed market share analysis in the Cancer Biologics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Biologics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Biologics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Biologics Market

A strategic analysis of the Cancer Biologics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biologics Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Incyte Corporation, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi, Seattle Genetics, and Takeda Pharmaceutical.

Market Segmentation & Coverage

This research report categorizes the Cancer Biologics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapies, market is studied across Bispecific Monoclonal Antibodies, Conjugated Monoclonal Antibodies, and Monoclonal Antibodies. The Conjugated Monoclonal Antibodies is further studied across Chemolabelled Antibodies and Radiolabelled Antibodies.
  • Based on Cell Therapies, market is studied across Dendritic Cell Therapy, Natural Killer Cell Therapy, and T-Cell Therapy.
  • Based on Cancer Vaccines, market is studied across Preventive Cancer Vaccines and Therapeutic Cancer Vaccines.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of initiatives focused on early cancer detection and personalized treatment options
      • 5.1.1.2. Technological advancements in biologic drug manufacturing leading to cost efficiency and higher production rates
      • 5.1.1.3. Increasing collaborations between academic institutions and biopharmaceutical companies for cancer drug innovation
      • 5.1.1.4. Expansion of healthcare infrastructure and access to biologics in emerging markets contributing to market growth
    • 5.1.2. Restraints
      • 5.1.2.1. Complex supply chain and cold storage logistics create challenges in distribution and increase costs
      • 5.1.2.2. Reimbursement and insurance coverage restrictions limit patient access to expensive biologics treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in immunotherapy techniques enhancing treatment effectiveness and market penetration
      • 5.1.3.2. Integrating artificial intelligence and machine learning in cancer biologics for predictive analytics
      • 5.1.3.3. Expansion of cancer biologics in emerging markets due to increased diagnostic capabilities
    • 5.1.4. Challenges
      • 5.1.4.1. Navigating complex regulatory approval processes for cancer biologics causing delays in market entry
      • 5.1.4.2. Challenges in obtaining robust clinical trial data for proving the efficacy and safety of cancer biologics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Biologics Market, by Therapies

  • 6.1. Introduction
  • 6.2. Bispecific Monoclonal Antibodies
  • 6.3. Conjugated Monoclonal Antibodies
    • 6.3.1. Chemolabelled Antibodies
    • 6.3.2. Radiolabelled Antibodies
  • 6.4. Monoclonal Antibodies

7. Cancer Biologics Market, by Cell Therapies

  • 7.1. Introduction
  • 7.2. Dendritic Cell Therapy
  • 7.3. Natural Killer Cell Therapy
  • 7.4. T-Cell Therapy

8. Cancer Biologics Market, by Cancer Vaccines

  • 8.1. Introduction
  • 8.2. Preventive Cancer Vaccines
  • 8.3. Therapeutic Cancer Vaccines

9. Americas Cancer Biologics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Biologics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Biologics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

LIST OF FIGURES

  • FIGURE 1. CANCER BIOLOGICS MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER BIOLOGICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CANCER BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CANCER BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER BIOLOGICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER BIOLOGICS MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY BISPECIFIC MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CHEMOLABELLED ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RADIOLABELLED ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY NATURAL KILLER CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PREVENTIVE CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 189. CANCER BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. CANCER BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2023